

DurVena, Inc.

DurVena is commercializing a novel photochemical tissue passivation therapy to strengthen vein grafts, improve long term graft patency, and address this unmet \$6B clinical opportunity for patients undergoing CABG, PAD, and AVF surgeries.



Company Overview

DurVena has an exclusive worldwide license to this novel therapy from Mass General Hospital and is founded and managed by an accomplished team of business professionals with several successful exits (\$1.25B in total investor returns) and extensive experience with start-up medical device development in this market sector. Broad claims covering the PTP method and devices for vein graft preparation have been issued around the world, and a several peer-reviewed pre-clinical papers showing the effects of PTP have been published by top medical journals.

Problem

Over 1 million Coronary Artery Bypass Graft (CABG), Peripheral Artery Disease (PAD), and Arteriovenous Fistula (AVF) procedures are performed in the U.S. annually. These procedures utilize the patients vein as a new graft for arterial blood flow. Structurally, veins are not designed to withstand arterial pressure. The vein grafts expand under the arterial pressure and are subject to reported degeneration and occlusion rates from 15-25% in the first year and as high as 50% at five years. Vein graft failure is associated with a significant increase in major adverse cardiovascular events (MACE), including death, myocardial infarction (MI), and the need for expensive and risky repeat revascularization.

Highlights

5 published pre-clinical peer reviewed journal articles

13 patents issued

Scientific Advisor Board of 6 KOLs

Prototypes completed and tested

Go-To-Market Strategy

Publish/present clinical trial results in top journals and medical conferences

Utilize internal sales management and combination of direct and contract regional sales representatives

Obtain CMMS New Technology Add-on Payment for reimbursing hospitals for our product.

Financial Info

Raising

\$2.15M

Location

Danville, CA, USA

Business Stage

Beta

Business Type

Healthcare

Meet the Team



John Ashley

CEO

What Makes Us Special

Over 100 years of experience developing and commercializing new medical

technologies.

8 exits (including 2 IPOs) that returned over \$1.25B to investors

Unmet clinical need that represents 3 distinct large market opportunities.

Raised \$5M to date (only 20 investors)

5 US and 5 OUS patents issued many more applications in process

5 published peer-reviewed preclinical papers

Strong SAB with KOLs from top academic centers